Plasma microRNA Panel for Indeterminate Pulmonary Nodule Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting lung cancer, such as LDCT and plasma biomarkers, suffer from over-diagnosis, excessive cost, radiation exposure, and low sensitivity and specificity, particularly in diagnosing indeterminate pulmonary nodules.
Innovation Solution
Utilizing a combination of microRNA biomarkers (miR205-5p and miR126) with pulmonary nodule size to predict non-small cell lung cancer, and a combination of miR-210, FUT8, and lncRNA SNHG1 to enhance diagnostic accuracy and treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If low-dose CT (LDCT) is used for lung cancer screening, then early detection capability is improved, but radiation exposure and over-diagnosis increase
Solution Approach 1:
The patent introduces plasma biomarkers (microRNAs, proteins, metabolites) as intermediary substances to detect lung cancer. These biomarkers serve as mediators between the cancer cells and the detection system, allowing identification of cancer presence through blood tests without requiring direct imaging exposure. The biomarkers are released by cancer cells into the bloodstream and can be measured non-invasively, thus eliminating radiation exposure while maintaining detection capability.
Solution Approach 2:
The patent replaces the mechanical/radiological detection system (LDCT scanning) with a biochemical detection system. Instead of using ionizing radiation to image pulmonary nodules, the invention uses laboratory assays to measure concentrations of cancer-specific biomarkers in plasma. This substitution transforms the detection mechanism from physical radiation-based imaging to chemical/biological marker analysis, eliminating harmful radiation effects.
2Reliability
If low-dose CT (LDCT) is used for lung cancer screening, then early detection capability is improved, but false positive rate and unnecessary procedures increase
Solution Approach 1:
The patent segments the detection approach by using multiple distinct biomarkers simultaneously rather than relying on a single imaging finding. By measuring several different cancer-specific markers (microRNAs, proteins, metabolites) in plasma, the system can cross-validate results. The presence of multiple elevated markers provides stronger evidence of true cancer, reducing false positives that might occur with single-marker or single-imaging approaches.
Solution Approach 2:
The patent employs a composite biomarker panel combining multiple types of molecular markers (microRNAs, proteins, and metabolites) detected through laboratory assays. This composite approach integrates information from different biological pathways and cancer processes, creating a more specific and accurate diagnostic signature. The combination of multiple marker types enhances measurement precision by providing complementary evidence that reduces false positive interpretations.
3Ease of operation
If plasma biomarkers are used for lung cancer detection, then non-invasive detection is achieved, but sensitivity and specificity remain low
Solution Approach 1:
The patent merges multiple previously separate detection approaches into a unified plasma biomarker panel. By combining measurements of microRNAs, proteins, and metabolites in a single plasma sample analysis, the invention creates a synergistic detection system. The combined information from these different marker types compensates for the limitations of individual markers, achieving both high sensitivity (detecting true cancer cases) and high specificity (excluding false positives) while maintaining non-invasive plasma sampling.
Solution Approach 2:
The patent applies parameter changes by utilizing multiple different biological parameters (concentrations of various microRNAs, proteins, and metabolites) rather than relying on a single parameter. By measuring and analyzing the pattern across multiple biomarker parameters simultaneously, the system enhances measurement precision. The multi-parameter approach allows for more accurate differentiation between cancer and non-cancer conditions, improving both sensitivity and specificity of the non-invasive detection method.
Data Source
AI summary
The present invention provides a method of predicting whether a pulmonary nodule in a subject is benign or non-small cell lung cancer, comprising obtaining the results of an assay that measures an expression level of miR205-5p in a plasma sample from the subject; obtaining the results of an assay that measures an expression level of miR126 in a plasma sample from the subject; obtaining the results of an assay that provides a size of the pulmonary nodule in the subject; and calculating a probability value based on the combination of the expression levels of miR205-5p and miR126, and the size of the pulmonary nodule, wherein if the probability value exceeds a specified threshold, the pulmonary nodule is predicted as non-small cell lung cancer.